Physician profile
Simone A Ince
NPI 1841327822
$15,295.74
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $354 · 2021: $14K · 2022: $559 · 2023: $23.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13,039.37 | 2021-2022 | |
| Abbvie INC. | $506.81 | 2019-2022 | |
| Amgen INC. | $427.79 | 2019-2022 | |
| Lilly USA, LLC | $303.70 | 2019-2022 | |
| Celgene Corporation | $229.06 | 2019 | |
| Janssen Biotech, INC. | $141.90 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $106.47 | 2019-2022 | |
| Genzyme Corporation | $90.62 | 2019-2021 | |
| Dermira, INC. | $66.18 | 2019-2020 | |
| Leo Pharma INC. | $65.05 | 2019-2023 | Adbry |
| Ucb, INC. | $61.19 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $50.38 | 2021-2022 | |
| Galderma Laboratories, L.P. | $31.23 | 2020-2021 | |
| Almirall LLC | $24.39 | 2022 | |
| Vyne Pharmaceuticals INC. | $23.46 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $20.25 | 2020 | |
| Pfizer INC. | $19.91 | 2021 | |
| Stemline Therapeutics INC. | $19.08 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.70 | 2022 | |
| Incyte Corporation | $15.68 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $15.07 | 2021 | |
| Sun Pharmaceutical Industries INC. | $13.36 | 2021 | |
| Biofrontera INC. | $7.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simone Ince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.